WHAT DOES BCAT-IN-4 MEAN?

MI-CP151 was a period 1b randomised, double-blind, placebo managed, dose-escalation, multicentre examine To guage various intravenous doses of sifalimumab, in adult clients with dermatomyositis or polymyositis (NCT00533091). Major demo targets have been To judge the safety and tolerability of sifalimumab in dermatomyositis or polymyositis clients,